[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pharmala Biotech Holdings Inc. (MDMA.CN)

Pharmala Biotech Holdings Inc. (MDMA.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 15,793
  • Shares Outstanding, K 108,918
  • Annual Sales, $ 605 K
  • Annual Income, $ -2,175 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 1.09
  • Price/Sales 17.17
  • Price/Cash Flow N/A
  • Price/Book 7.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1400 +3.57%
on 05/19/26
0.1950 -25.64%
on 05/20/26
-0.0150 (-9.38%)
since 04/22/26
3-Month
0.0850 +70.59%
on 04/09/26
0.1950 -25.64%
on 05/20/26
+0.0450 (+45.00%)
since 02/20/26
52-Week
0.0850 +70.59%
on 04/09/26
0.1950 -25.64%
on 05/20/26
+0.0150 (+11.54%)
since 05/22/25

Most Recent Stories

More News
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF) (“ PharmAla ” or the “ Company ”), a global leader in the research, development, and manufacturing...

MDXXF : 0.1058 (-6.70%)
JUNS : 0.2378 (-12.19%)
MDMA.CN : 0.1450 (-9.38%)
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic Medicine JUPITER, FL, May...

JUNS : 0.2378 (-12.19%)
MDXXF : 0.1058 (-6.70%)
MDMA.CN : 0.1450 (-9.38%)
PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) ( “PharmAla” or the “Company” ), a leader in the research, development, and manufacturing...

MDXXF : 0.1058 (-6.70%)
MDMA.CN : 0.1450 (-9.38%)
Upcoming Meeting Dates - May 11, 2026

Toronto, Ontario -- (Newsfile Corp. - May 11, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies through...

GRB.VN : 0.560 (unch)
SHRX.VN : 2.100 (-2.33%)
CURA.TO : 4.62 (-1.49%)
STGO.TO : 1.16 (-4.92%)
IMC.VN : 0.025 (unch)
ULTH.CN : 0.2050 (unch)
RNCH.VN : 0.055 (unch)
AIC.CN : 0.4000 (unch)
BTC.CN : 0.1100 (unch)
ADYA.VN : 0.370 (unch)
FHR.VN : 0.075 (unch)
CVW.VN : 1.140 (-3.39%)
PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) (“PharmAla” or the “Company”), a biotechnology company focused on the research, development,...

MDXXF : 0.1058 (-6.70%)
MDMA.CN : 0.1450 (-9.38%)
PharmAla Issues Q2 Financial Statements and Grants Options

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development,...

MDXXF : 0.1058 (-6.70%)
MDMA.CN : 0.1450 (-9.38%)
PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) ("PharmAla" or the "Company"), a global leader in the research, development and manufacturing of MDMA...

MDXXF : 0.1058 (-6.70%)
MDMA.CN : 0.1450 (-9.38%)
Cortexa Advances Commercialisation of MDMA Supply in Australia

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading psychedelic medicines supplier, reaffirms its market leading position in FY2026 for MDMA (3,4-methylenedioxymethamphetamine)....

MDXXF : 0.1058 (-6.70%)
VIT.AX : 0.035 (-2.78%)
MDMA.CN : 0.1450 (-9.38%)
PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA...

MDXXF : 0.1058 (-6.70%)
MDMA.CN : 0.1450 (-9.38%)
PharmAla Signs Drug Donation Agreement for MDMA-Assisted Therapy Clinical Trial in Fibromyalgia

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA...

MDXXF : 0.1058 (-6.70%)
MDMA.CN : 0.1450 (-9.38%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active...

See More

Key Turning Points

3rd Resistance Point 0.1700
2nd Resistance Point 0.1650
1st Resistance Point 0.1550
Last Price 0.1450
1st Support Level 0.1400
2nd Support Level 0.1350
3rd Support Level 0.1250

See More

52-Week High 0.1950
Fibonacci 61.8% 0.1530
Last Price 0.1450
Fibonacci 50% 0.1400
Fibonacci 38.2% 0.1270
52-Week Low 0.0850

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.